Emergency Procedures & Response Flashcards

A sponsor issues an urgent safety communication notifying investigators of a new contraindication discovered during a trial. The investigator's FIRST action should be:

Answer: Review currently enrolled participants for the contraindication and take protective action immediately

Upon receipt of urgent safety communications, investigators must immediately assess enrolled participants for risk and take protective action without delay.

Under GCP guidelines, which document formally authorizes staff to manage emergencies at a clinical trial site?

Answer: The site's delegation of authority log signed by the PI

The delegation of authority log specifies which staff members are authorized to perform specific study tasks, including emergency medical response procedures.

A participant who was lost to follow-up contacts the site reporting a hospitalization that occurred two months ago. The investigator should:

Answer: Assess the event for seriousness, document it thoroughly, and report if it meets SAE criteria

Retrospective SAE reports must still be assessed, documented, and reported if they meet SAE criteria; there is no regulatory exemption for late discovery.

Which of the following best describes the 'stopping rules' in a clinical trial protocol?

Answer: Predefined criteria that trigger immediate discontinuation of a participant or the entire trial

Stopping rules are pre-specified safety thresholds in the protocol that mandate participant withdrawal or trial suspension when specific adverse events or data patterns occur.

When a natural disaster disrupts a clinical trial site and participants cannot be reached for scheduled study visits, the investigator's primary obligation is to:

Answer: Ensure participant safety and document the force majeure event, notifying the IRB and sponsor

In force majeure events, participant safety takes priority; the investigator must document the disruption and notify oversight bodies per protocol and regulatory requirements.

A participant reveals during an emergency room visit that they are concurrently enrolled in another drug trial without the investigator's knowledge. The investigator should:

Answer: Document the dual enrollment, assess safety risks, notify the IRB and sponsor, and determine eligibility impact

Undisclosed dual enrollment is a protocol deviation that must be documented and reported; the investigator must assess potential drug interactions and inform oversight bodies.

When a clinical trial is terminated early due to safety concerns, the investigator is required to:

Answer: Notify all participants, ensure appropriate follow-up care, and submit a final report to the IRB

Early termination requires notifying all participants, arranging appropriate medical follow-up, and submitting closure reports to the IRB and sponsor per regulatory requirements.